---
title: "Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Fulvestrant, aromatase inhibitors, and tamoxifen"
description: "Formulary evidence on Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Fulvestrant, aromatase inhibitors, and tamoxifen. Topics: Guideline recommendation: NCCN, endocrine monotherapy; Guideline recommendation: NCCN, fulvestrant dose; Comparator regulatory information: fulvestrant; Comparator regulatory information: exemestane; 9 further topics. 13 evidence topics quoted from 13 sources."
canonical: "https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/product-information-and-disease-description/fulvestrant-aromatase-inhibitors-and-tamoxifen"
published: "2026-11-15T20:23:25-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Fulvestrant, aromatase inhibitors, and tamoxifen

<a id="heading-2.2.2.1.4"></a>

## 2.2.2.1.4 Fulvestrant, Aromatase Inhibitors, and Tamoxifen

<a id="topic-2.2.2.1.4-1"></a>

### Guideline recommendation: NCCN, endocrine monotherapy

> “AIs as monotherapy are options as subsequent-line therapy. The 3 AIs (anastrozole, letrozole, and exemestane) have shown similar efficacy in the second-line setting.”
> “Patients who have received a prior nonsteroidal AI may benefit from a steroidal AI as a subsequent line of therapy or vice versa.”
> “An analysis of 2 randomized studies of first-line treatment with anastrozole followed by second-line tamoxifen and vice versa showed that tamoxifen is effective as a second-line option.”
> “The clinical benefit rates of fulvestrant versus exemestane in a phase III trial of postmenopausal patients with HR-positive advanced breast cancer who experienced disease progression on prior nonsteroidal AI therapy were observed to be comparable (32.2% vs 31.5%; P=.853).”

Source: [Gradishar et al. (2026)](https://jnccn.org/view/journals/jnccn/24/7/article-e260033.xml)

<a id="topic-2.2.2.1.4-2"></a>

### Guideline recommendation: NCCN, fulvestrant dose

> “The PFS was superior with the fulvestrant 500 mg regimen (HR, 0.80; 95% CI, 0.68–0.94; P=.006),74 indicating an increased duration of response (DOR) with the higher dose of fulvestrant.”
> “Median OS was 26.4 versus 22.3 months (HR, 0.81; 95% CI, 0.69–0.96; P=.02).”

Source: [Gradishar et al. (2026)](https://jnccn.org/view/journals/jnccn/24/7/article-e260033.xml)

<a id="topic-2.2.2.1.4-3"></a>

### Comparator regulatory information: fulvestrant

> “HR-positive advanced breast cancer in postmenopausal women with disease progression following endocrine therapy.”
> “The recommended dose of FASLODEX is 500 mg to be administered intramuscularly into the buttocks (gluteal area) slowly (1 - 2 minutes per injection) as two 5 mL injections, one in each buttock, on Days 1, 15, 29, and once monthly thereafter”

Source: [Faslodex prescribing information (2021)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/021344s044lbl.pdf)

<a id="topic-2.2.2.1.4-4"></a>

### Comparator regulatory information: exemestane

> “AROMASIN is indicated for the treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy”
> “The recommended dose of AROMASIN in early and advanced breast cancer is one 25 mg tablet once daily after a meal.”

Source: [Aromasin prescribing information (2024)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/020753s025lbl.pdf)

<a id="topic-2.2.2.1.4-5"></a>

### OPERA-01 control arm: standard-of-care endocrine monotherapy

> “Fulvestrant or the AIs letrozole, anastrozole, or exemestane (with gonadal suppression in pre- and perimenopausal women or men) are included as the physician’s choice of SOC ET monotherapy for the control arm. The SOC ET in the control arm aligns with the NCCN and ASCO guidelines recommending ET monotherapy as a treatment option to delay chemotherapy”
> “Fulvestrant was recommended to patients who have not previously received fulvestrant.”

Source: [Pistilli et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12802986/)

<a id="topic-2.2.2.1.4-6"></a>

### Endocrine monotherapy after a CDK4/6 inhibitor: EMERALD control arm

> “However, the clinical activity of endocrine monotherapy in patients who have received prior CDK4/6 or mammalian target of rapamycin inhibition is limited, with a median progression-free survival (PFS) of approximately 2 months, highlighting a major unmet clinical need in the field.”
> “SOC treatment was per investigator's choice of fulvestrant, anastrozole, letrozole, or exemestane monotherapy and dosed according to the labeling.”

Source: [Bidard et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9553388/)

<a id="topic-2.2.2.1.4-7"></a>

### Endocrine monotherapy after a CDK4/6 inhibitor: EMERALD control arm in ESR1-mutated disease

> “The median PFS was 3.8 months (95% CI, 2.2 to 7.3) in the elacestrant arm and 1.9 months (95% CI, 1.9 to 2.1) in the SOC arm.”

Source: [Shah et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11003513/)

<a id="topic-2.2.2.1.4-8"></a>

### Fulvestrant or exemestane: EMBER-3 control arm

> “Patients received INLURIYO 400 mg orally, once daily (n=327), or standard of care (n=324) consisting of either fulvestrant (n=292) or exemestane (n=32).”

Source: [Inluriyo prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/218881s001lbl.pdf)

<a id="topic-2.2.2.1.4-9"></a>

### Fulvestrant or exemestane: EMBER-3 control arm outcomes

> “Among 256 patients with ESR1 mutations, the median progression-free survival was 5.5 months with imlunestrant and 3.8 months with standard therapy.”
> “In the overall population, the median progression-free survival was 5.6 months with imlunestrant and 5.5 months with standard therapy (hazard ratio for progression or death, 0.87; 95% CI, 0.72 to 1.04; P = 0.12).”

Source: [Jhaveri et al. (2025a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13674379/)

<a id="topic-2.2.2.1.4-10"></a>

### Fulvestrant: VERITAC-2 control arm outcomes

> “Among the 270 patients with ESR1 mutations, the median progression-free survival was 5.0 months (95% confidence interval [CI], 3.7 to 7.4) with vepdegestrant and 2.1 months (95% CI, 1.9 to 3.5) with fulvestrant (hazard ratio, 0.58 [95% CI, 0.43 to 0.78]; P<0.001).”
> “Among all the patients, the median progression-free survival was 3.8 months (95% CI, 3.7 to 5.3) with vepdegestrant and 3.6 months (95% CI, 2.6 to 4.0) with fulvestrant”

Source: [Campone et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40454645/)

<a id="topic-2.2.2.1.4-11"></a>

### Fulvestrant: CAPItello-291 control arm outcomes

> “In the overall population, the median progression-free survival was 7.2 months in the capivasertib–fulvestrant group, as compared with 3.6 months in the placebo–fulvestrant group (hazard ratio for progression or death, 0.60; 95% confidence interval [CI], 0.51 to 0.71; P<0.001).”

Source: [Turner et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11335038/)

<a id="topic-2.2.2.1.4-12"></a>

### Fulvestrant: VIKTORIA-1 control arm outcomes

> “The median progression-free survival was 9.3 months in the gedatolisib-triplet group, 2.0 months in the fulvestrant group (hazard ratio [HR] for progression or death, 0.24 [95% CI, 0.17 to 0.35]; P < .001), and 7.4 months in the gedatolisib-doublet group (HR, 0.33 [95% CI, 0.24 to 0.48]; P < .001 v fulvestrant).”

Source: [Hurvitz et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13075786/)

<a id="topic-2.2.2.1.4-13"></a>

### Endocrine monotherapy in the second line: real-world progression-free survival

> “the weighted average median rwPFS was calculated as 3.9 months (3.3-6.0 months) for single-agent ET, 3.6 months (2.5–4.9 months) for mTORi ± ET, 3.7 months for a mix of ET and/or mTORi (3.0–4.0 months), and 6.1 months (3.7–9.7 months) for chemotherapy.”
> “The real-world effectiveness of current 2 L treatments post-1 L CDK4/6i are suboptimal, highlighting an unmet need for this patient population.”

Source: [Lambert et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11112888/)

Additional sources: [de Azambuja et al. (2026)](https://www.annalsofoncology.org/article/S0923-7534(26)00902-6/fulltext)

## Related pages
- [Palazestrant (OP-1250): Previously treated ER-positive HER2-negative advanced or metastatic breast cancer](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Terms and abbreviations](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/terms-and-abbreviations.md)
- [Palazestrant (OP-1250): Previously treated ER-positive HER2-negative advanced or metastatic breast cancer](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/executive-summary) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/executive-summary.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Product information and disease description](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/product-information-and-disease-description.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Clinical evidence](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/clinical-evidence.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Economic information and modeling report](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/economics) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/economics.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: References](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/references) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/references.md)
